Abstract 1487P
Background
As thyroid hormones modulate proliferative and angiogenic pathways, it is surmised that they can be associated with cancer development. Since the potential association of gastroesophageal cancer and thyroid disorders has not been addressed so far, the aim of this study was to investigate the impact of thyroid hormone parameters on the outcome of these patients, so novel diagnostic, prognostic and even potentially therapeutic markers can be defined.
Methods
We analyzed clinical and endocrinological parameters including history of endocrinological disorders and laboratory analyses of thyroid hormones at first cancer diagnosis and correlated these with the overall survival (OS) of patients with resectable gastroesophageal cancer treated between 2002 and 2018 at the Vienna General Hospital, Austria.
Results
In total, the survival outcome of 867 patients (155 stage I, 276 stage II and 423 stage III) was evaluated. The TSH, T3, T4, fT3 and fT4 levels did not significantly impact the OS, neither did thyroid disorders. Interestingly, thyroid replacement therapy was associated with a significant longer OS [without (n=55): 30.6, with (n=67): 51.3 months; p=0.044].
Conclusions
Thyroid disorders and their therapeutic interventions might be associated with the OS in patients with resectable gastroesophageal cancer. Since data on the correlation of these parameters are scarce, this analysis is an important impulse for further studies concerning the impact of thyroid hormones on patients with gastroesophageal tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H.C. Puhr: Travel/Accommodation/Expenses: Eli Lilly; Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Roche. A.S. Berghoff: Research grant/Funding (self), Travel/Accommodation/Expenses: Daiichi Sankyo ; Honoraria (self), Research grant/Funding (self), Travel/Accommodation/Expenses: Roche; Honoraria (self): Bristol-Meyers Squibb; Honoraria (self): Merck; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: AbbVie. M. Preusser: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Bayer; Honoraria (self): Novartis; Honoraria (self): Gerson Lehrman Group (GLG); Honoraria (self): CMC Contrast; Honoraria (self): GlaxoSmithKline; Honoraria (self): Mundipharma; Honoraria (self): Roche; Honoraria (self): MedMedia; Honoraria (self): Astra Zeneca; Honoraria (self): AbbVie; Honoraria (self): Lilly; Honoraria (self): Medahead; Honoraria (self): Daiichi Sankyo; Honoraria (self): MSD. A. Ilhan-Mutlu: Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (institution): Astellas; Honoraria (institution): BMS. All other authors have declared no conflicts of interest.